Key Events This Week
30 Mar: Stock drops 3.39% amid broad market weakness
1 Apr: Intraday high of Rs.344.20 with 7.65% gain
2 Apr: Investment rating upgraded to Sell, stock rises 1.37%
3 Apr: No trading data available, week closes at Rs.352.05

Aarti Drugs Ltd Investment Rating Upgraded to Sell on Improving Fundamentals
2026-04-02 08:16:14Aarti Drugs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026, reflecting a nuanced reassessment of its financial performance, valuation metrics, management efficiency, and technical indicators. Despite ongoing challenges in profitability and operating trends, certain valuation and efficiency parameters have improved, prompting a more balanced outlook for this small-cap pharmaceutical player.
Read full news article
Aarti Drugs Ltd Surges 7.65% to Day's High of Rs 344.2 — Outperforms Sector by 6.28 Percentage Points
2026-04-01 10:45:59The Sensex declined by 2.15% on 1 Apr 2026, yet Aarti Drugs Ltd surged 7.65%, marking a 6.28 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, raising the question of whether this is a genuine recovery or a technical bounce within a broader downtrend.
Read full news article
Aarti Drugs Ltd is Rated Strong Sell
2026-03-31 10:10:37Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Aarti Drugs Ltd is Rated Strong Sell
2026-03-20 10:10:45Aarti Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article









